This Article Full Text (OnlineFirst[PDF]) Order Full text via Infotrieve All Versions of this Article: 0962280207081863v1 0962280207081863v2    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Google Scholar Articles by Green, E.M. Articles by Sargent, D. J. PubMed PubMed Citation Articles by Green, E.M. Articles by Sargent, D. J. Social Bookmarking                   What's this?

Surrogate endpoint validation: statistical elegance versus clinical relevance

¹ Division of Biostatistics, Mayo Clinic, Rochester, MN, USA
² NSABP Statistical Center, Pittsburgh, PA, USA
³ Division of Biostatistics, MayoClinic, Rochester, MN, USA

^* To whom correspondence should be addressed.

	Abstract

A variety of approaches have been proposed to provide formal and informal validation of proposed surrogate markers. To achieve true clinical impact, the validation must convince both the statistical and clinical communities. In this paper, we argue that the best approach is not a single method but a multi-faceted exploration, using multiple approaches, including those that directly appeal to clinicians but with less statistical foundation and those arising from statistical considerations but more difficult to interpret clinically. We illustrate our approach using data from clinical trials in both early and advanced colorectal cancer.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?